> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Bio-Techne's $0.08 Dividend Gets Paid Only If The Merck KGaA Deal Is Still Open On November 13
- URL: https://www.bullished.co/bio-technes-0-08-dividend-gets-paid-only-if-the-merck-kgaa-deal-is-still-open-on-november-f8362c4b/
- Published: 2026-11-04T11:24:36.000Z
- Updated: 2026-11-04T11:24:36.000Z
- Description: The quarterly payout depends on whether the pending Merck KGaA transaction has closed by the record date, the company said.
- Author: Matteo Parrino
- Tags: SEC Filings, TECH, Industry: Healthcare

Bio-Techne, which makes life science reagents, instruments and services, declared a [$0.08-per-share dividend](https://www.sec.gov/Archives/edgar/data/0000842023/000110465926122283/tech-20261103x8k.htm?ref=bullished.co) on Tuesday, but holders collect it only if its previously announced transaction with Merck KGaA, Darmstadt, Germany has not closed by the close of business on November 13.

## A payout with a deal-closing trigger

The board set the dividend for the quarter ended September 30, 2026\. It is payable November 23 to common shareholders of record at the close of business on November 13, according to the company's [press release](https://www.sec.gov/Archives/edgar/data/0000842023/000110465926122283/tech-ex99d1.htm?ref=bullished.co).

The condition is explicit: the payment applies "provided" the Merck KGaA transaction has not closed on or before that November 13 cutoff. If the deal closes first, the dividend is not paid.

The release also said the board will consider future cash dividends on a quarterly basis, as applicable. It describes the Merck KGaA deal as a pending acquisition of Bio-Techne by the German company.

## What Bio-Techne sells

Bio-Techne develops, manufactures and sells reagents, instruments and services for research, diagnostics and bioprocessing customers worldwide. Its Protein Sciences segment, which makes proteins, antibodies and other reagents, was about 72% of net sales in fiscal 2026, according to the company's annual report. Diagnostics and Spatial Biology, which makes diagnostic controls, calibrators and tissue-analysis tools, was about 28%.

The company said it generated over $1.2 billion in net sales in fiscal 2026 and had approximately 3,000 employees worldwide. It is based in Minneapolis.

## Deal risks the company flags

In its forward-looking statements, the company listed the timing of the deal's completion, including whether it happens on or before the record date, as a risk. It also cited the conditions to closing, including required shareholder and regulatory approvals, and the effect of the pending deal on its business and stock price.

Whether the Merck KGaA transaction closes on or before November 13 decides if the $0.08 is paid on November 23.

Learn

- [Item 8.01: other events →](https://www.bullished.co/learn/8-k-items-explained/#item-801-other-events)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — BIO-TECHNE Corp (TECH)](https://www.sec.gov/Archives/edgar/data/0000842023/000110465926122283/tech-20261103x8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit tech-ex99d1.htm — BIO-TECHNE Corp 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000842023/000110465926122283/tech-ex99d1.htm?ref=bullished.co) — SEC EDGAR